An interventional study of Abbott ID NOW Point-of-Care Testing and Standard Laboratory-Based RT-PCR Diagnostic Pathway in Influenza and Influenza-like Illness, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by China Medical University Hospital · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Influenza, Human with a site in Taiwan — 6 open to participants now, 6 under way, 2 of them phase 3. Influenza, Human · Taiwan.
Among the 52 studies in Influenza, Human with a site in Taiwan, this one is the 14th largest by planned enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 52nd registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →6 of the 52 studies in Influenza, Human with a site in Taiwan are open now. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 65+
National Taiwan University Hospital · Sites in Taiwan
Ages 6 mo–18 yrs
AstraZeneca · Sites in Taiwan, United States, Argentina and 36 more countries
Ages 18+
Far East Bio-Tec Co., Ltd · Sites in Taiwan
Ages 20–65
China Medical University Hospital · Sites in Taiwan
Ages 20+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 24 · Phase 4 6
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,080 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 300 across the 47 interventional studies, 54 across the 5 observational. Of the 41 that completed or were terminated, 19 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 52 have an industry lead sponsor. The 10 most frequent:
China Medical University Hospital is the lead sponsor of 480 studies on the registry; 116 are open to participants now.
China Medical University Hospital has 2 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
2 of the studies in Influenza, Human with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT01677689Far East Bio-Tec Co., LtdStudy to Investigate the Efficacy and Safety of Apomivir® | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Influenza, Human with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
With the rapid aging of the global population, long-term care facilities (LTCFs) have become an increasingly important component of modern public health systems. However, these settings are also at high risk for outbreaks of respiratory infectious diseases. Influenza virus transmission within LTCFs has distinct epidemiological characteristics, including high transmissibility and high risks of severe illness and mortality. In Taiwan, with the accelerated aging of the population, LTCF residents commonly have multiple chronic comorbidities (multimorbidity) and age-related immune dysfunction (immunosenescence). Influenza infection in this population may not only lead to acute respiratory failure but may also contribute to a "silent burden," including post-infection cardiovascular events, metabolic dysregulation, and long-term functional decline.
Under the current standard of care (SOC), influenza diagnosis relies on reverse transcription polymerase chain reaction (RT-PCR) testing performed by external laboratories, with a turnaround time (TAT) of approximately 24 to 48 hours. This time-to-result gap may delay clinical decision-making, potentially preventing timely initiation of antiviral treatment within the optimal 48-hour treatment window and leading facilities to adopt broad precautionary isolation measures, thereby increasing healthcare resource utilization and staffing burden.
The Abbott ID NOW system uses isothermal nucleic acid amplification technology (INAAT) and can provide molecular diagnostic results within approximately 15 minutes. Through a prospective cluster-randomized controlled design, this study aims to evaluate whether implementation of an ID NOW-based point-of-care testing (POCT) strategy can improve clinical outcomes among LTCF residents and reduce overall healthcare costs compared with the current standard diagnostic pathway.
Long-term care facilities (LTCFs) play an increasingly important role in healthcare systems as populations age. However, LTCFs are also settings with a high risk of respiratory infectious disease transmission. Influenza outbreaks in these facilities are of particular concern because residents often have advanced age, multiple chronic comorbidities, and age-related immune dysfunction, all of which may increase the risks of severe disease, hospitalization, and mortality. In addition to acute respiratory complications, influenza infection in this population may also be associated with subsequent cardiovascular events, metabolic deterioration, and prolonged functional decline.
In current clinical practice, influenza diagnosis in LTCFs commonly relies on reverse transcription polymerase chain reaction (RT-PCR) testing performed by external laboratories. The interval between specimen collection and reporting of results may be approximately 24 to 48 hours. This delay may affect the timing of clinical decision-making, including initiation of antiviral therapy and implementation of infection prevention and control measures. During the period when diagnostic results are unavailable, LTCFs may also need to implement precautionary isolation or cohorting measures for residents with suspected influenza-like illness, which may increase healthcare resource utilization and staff workload.
The Abbott ID NOW system is a rapid molecular diagnostic platform based on isothermal nucleic acid amplification technology (INAAT) and can provide molecular test results within approximately 15 minutes. The availability of rapid molecular testing at the point of care may shorten the time between clinical suspicion, diagnostic testing, and subsequent management decisions.
This study is designed as a prospective, cluster-randomized, open-label, two-arm, active-controlled study to evaluate the impact of two different influenza diagnostic strategies in residents of LTCFs in Taiwan: an ID NOW-based point-of-care testing strategy and the current standard diagnostic pathway. The study aims to determine whether the implementation of rapid point-of-care molecular testing can improve clinical outcomes and healthcare resource utilization compared with the standard diagnostic approach.
The study is planned to be conducted in 8 to 10 legally registered residential LTCFs, including nursing homes and other long-term care institutions, located in northern, central, southern, and eastern Taiwan. Participating facilities are required to have at least 40 approved beds, sufficient healthcare personnel to follow the study procedures, the ability to perform on-site specimen collection and infection-control measures, and an established system of regular physician visits. Institutional management approval is required before a facility enters the randomization process.
Specific participating rooms within the study facilities will be designated for study participation. Residents living in these participating rooms will be considered potential participants during the study period. Enrollment will be event-driven rather than based on routine screening of all residents. Nursing staff at participating LTCFs will monitor residents for acute clinical events suggestive of influenza-like illness. When a resident develops symptoms or signs that meet the study inclusion criteria, the responsible physician will perform a clinical assessment to determine whether the resident is potentially eligible and to exclude alternative diagnoses that clearly explain the clinical presentation. After eligibility assessment and informed consent, the resident will be formally enrolled in the study.
Eligible participants may include residents with acute onset of fever, decreased oxygen saturation, respiratory symptoms, or clinical suspicion of influenza. Specific eligibility criteria include acute illness with tympanic temperature of at least 38°C persisting for at least 24 hours; acute illness associated with decreased oxygen saturation or deterioration in oxygenation; influenza infection highly suspected by the treating physician; residents aged 65 years or older with relevant comorbidities who develop acute illness with tympanic temperature of at least 37.5°C persisting for at least 24 hours; or at least one respiratory symptom, such as cough, sore throat, or rhinorrhea, persisting for at least 24 hours.
Residents will be excluded if an alternative definite diagnosis is identified at the initial assessment that adequately explains the influenza-like illness, including conditions such as bacterial pneumonia, non-respiratory infection, aspiration pneumonia, definite urinary tract infection, or exacerbation of heart failure without evidence of infection. Additional exclusion criteria include refusal to provide informed consent, expected survival of less than 48 hours, previous participation in the study within the preceding 14 days, and residence in a dedicated dementia care unit.
In the intervention group, eligible residents with suspected influenza-like illness will undergo point-of-care molecular testing using the Abbott ID NOW system. Nasal or nasopharyngeal swab specimens will be collected at the LTCF, and the test result will be available rapidly to support subsequent clinical and infection-control decisions. In the control group, residents will be managed according to the current standard diagnostic pathway, which relies on conventional laboratory-based RT-PCR testing and routine clinical management.
The study is open-label because the diagnostic strategy assigned to each group cannot be concealed from healthcare personnel. The study uses a parallel two-group design with active comparison between the ID NOW point-of-care testing strategy and the standard diagnostic pathway.
A total of 1,080 participants are planned for enrollment. The minimum eligible age is 20 years, with no specified upper age limit. Each enrolled participant will be followed for 30 days after the qualifying influenza-like illness event.
Clinical and healthcare utilization data will be collected during the follow-up period to evaluate differences between the two diagnostic strategies. The study is intended to provide evidence on whether rapid point-of-care molecular testing can shorten the diagnostic process, support more timely clinical and infection-control decision-making, improve resident outcomes, and reduce unnecessary healthcare resource utilization and overall healthcare costs in LTCFs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive point-of-care molecular testing for suspected influenza using the Abbott ID NOW system at the participating long-term care facility. Nasal or nasopharyngeal swab specimens will be collected on site, and the rapid test result will be used to support subsequent clinical management and infection prevention and control decisions.
Device: Abbott ID NOW Point-of-Care Testing
Participants in this arm will receive the current standard diagnostic pathway for suspected influenza, including laboratory-based reverse transcription polymerase chain reaction (RT-PCR) testing performed through the usual external laboratory process, together with routine clinical management and infection-control measures.
Diagnostic Test: Standard Laboratory-Based RT-PCR Diagnostic Pathway
Abbott ID NOW is a rapid molecular diagnostic platform based on isothermal nucleic acid amplification technology for the detection of influenza. Testing will be performed at the participating long-term care facility using nasal or nasopharyngeal swab specimens collected from eligible residents with suspected influenza-like illness. The system can provide molecular test results within approximately 15 minutes.
Standard-of-care influenza testing using reverse transcription polymerase chain reaction (RT-PCR) performed through the usual external laboratory workflow. Test results are generally available within approximately 24 to 48 hours and are used together with routine clinical assessment to guide subsequent management and infection-control decisions.
Time From Specimen Collection to Availability of Influenza Test Result
Time elapsed between collection of the respiratory specimen and availability of the influenza test result for clinical decision-making, compared between the ID NOW point-of-care testing strategy and the standard laboratory-based RT-PCR diagnostic pathway.
Time frame: During the index influenza-like illness episode, from specimen collection to availability of the test result, up to 48 hours
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.
Of 147 non-industry interventional studies with no phase under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 14 months is above that.
Counting every sponsor, half of 167 studies reached it within 6 months; a quarter within 3 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China Medical University Hospital →